| Study | Category of Trial | Enrollment Status |
|---|---|---|
| A5128: US Genomic Sampling Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. |
Non-Interventional | Active, Not Recruiting |
| A5243: Non-US Genomic Sampling Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. |
Non-Interventional | Open and Enrolling |
| A5300B/I2003B:Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Participants (PHOENIx) This trial is in household contacts (HHC) at high risk for developing multidrug resistant tuberculosis (MDR-TB) which is an infection that does not get better with standard treatment for TB. |
Treatment Experienced | Open and Enrolling |
| A5312: The Early Bactericidal Activity of High Dose or Standard Dose Isoniazid among adult Participants with Isoniazid-Resistant or Drug Sensitive Tuberculosis This study is for participants who have pulmonary tuberculosis (TB), a bacterial infection in their lungs. |
Tuberculosis | Closed to Accrual |
| A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study Studies differences and changes over time in HIV reservoirs (groups of HIV infected cells that ’hide’ from anti-HIV medications). |
Treatment Experienced | Open and Enrolling |
| A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) You are being asked to take part in this research study because you are infected with HIV, the virus that causes AIDS, and were previously followed in the ALLRT (A5001) study and are 40 years of age or older. |
Treatment Experienced | Closed to Accrual |
| A5332: REPRIEVE Trial In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin) to take the pill pitavastatin OR a placebo (non-active pill) to see if pitavastatin can help prevent heart disease and death in people who are taking HIV medication. |
Treatment Experienced | Closed to Accrual |
| A5343: A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, among Participants Taking Multidrug Treatment for Drug-Resistant Pulmonary Tuberculosis This is a randomized study, which means, by chance, you will be in one of three groups. |
Treatment ExperiencedTuberculosis | Closed to Accrual |
| A5354: Early ART in Acute HIV Will evaluate whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas of the body (reservoirs) and change how the immune system helps to control the virus. |
Treatment Naïve | Closed to Accrual |
| A5355: Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function Brief Background and Description: Since the early days of the HIV epidemic cytomegalovirus (CMV) has been one of the most common and devastating opportunistic infections (OIs) experienced by people with HIV. |
Treatment Experienced | Open and Enrolling |
| A5356: A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Tuberculosis ... |
Tuberculosis | Open and Enrolling |
| A5357: A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1 This study is for people with HIV who have an undetectable viral load. |
Treatment Experienced | Closed to Accrual |
| A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) Aging with HIV may be associated with an earlier development of frailty (weakness) or disability, including difficulties in tests of strength or walking speed. |
Treatment Experienced | Closed to Accrual |
| A5364: A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption ACTG A5364: A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combinatio... |
Treatment Experienced | Open and Enrolling |
| A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors While antiretrovirals known as ARV’s (group of medicines used to treat HIV) have provided very effective treatment of HIV, cure of HIV from the body has not been possible. |
Women | Closed to Accrual |
| A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy “Safety and Immunotherapeutic Activity of Cemiplimab in Participants with HBV on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose Study” Brief Description: Scientists are looking at ways to cure Hepatitis B (HBV). |
Treatment Experienced | Temporarily Closed |
| A5371: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) Short Title: The Slim Liver Study Brief Description: About 30-40% of people living with HIV have a condition called NAFLD, or non-alcoholic fatty liver disease. |
Hepatitis | Closed to Accrual |
| A5372: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study) The purpose of this research study is see if taking medications to prevent tuberculosis (TB) affect the drug levels in blood of a commonly used HIV medication called dolutegravir (DTG) and if an extra dose of DTG is needed during this TB preventive treatment. |
Tuberculosis | Temporarily Closed |
| A5377: Tri-specific Antibody The first study of a broadly neutralizing antibody called SAR441236 in humans, will determine if an infusion is safe and tolerable and will measure the amount of SAR441236 in the blood over time. |
Treatment Experienced | Open and Enrolling |
| A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B A5379 is a study looking at hepatitis B vaccination in adults living with HIV. |
Hepatitis | Temporarily Closed |
| A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) This is a study to treat participants, with or without HIV, who are found to have been recently infected with the Hepatitis C virus (HCV). |
Hepatitis | Closed to Accrual |
| A5381: Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART This is a study for people who have HIV and qualify to switch to or receive Dolutegravir containing antiretroviral therapy (ART, group of medicine used to treat HIV). |
Treatment Experienced | Closed to Accrual |
| A5386: N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART Full Title: A Phase 1 Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) with and without Combination B... |
Treatment Experienced | Open and Enrolling |
| A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study) ACTG A5391: Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study) Treatment Category: Treatm... |
Treatment Experienced | Open and Enrolling |
| A5394: Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg ... |
Hepatitis | Open and Enrolling |
| A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Study Description: A master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19. |
COVID-19 | Closed to Accrual |
| A5404: SARS-CoV-2 Immune Responses after COVID-19 Therapy and Vaccine Right now there is no medicine proven to treat COVID-19 in people who are not sick enough to be hospitalized. |
COVID-19 | Closed to Accrual |
| A5407: Placebo-controlled Phase 3 Outpatient Trial of Shionogi Agent for Treatment of Symptomatic SARS-CoV-2 Infection ... |
COVID-19 | Open and Enrolling |
| A5415: A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV ... |
Treatment Experienced | Open and Enrolling |
| A5418:Study of Tecovirimat for Human Monkeypox Virus (STOMP) ACTG A5418: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monk... |
Non-Interventional | Open and Enrolling |
| ACTG A5359: Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV (PLWH) Treatment Category: Treatment Experienced Study Description This four-step study compares Long-Acting (LA) Injectable Antiretroviral Therapy (ART) to standard of care (SOC) oral ART in previously non-adherent individuals. |
Treatment Experienced | Open and Enrolling |
| ACTG A5362: A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study Study Description A5362 is a study for people with pulmonary tuberculosis (TB) without evidence of resistance to the TB drugs isoniazid (INH) or rifampin (RIF). |
Treatment Experienced | Temporarily Closed |
| ACTG A5383: Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT) Brief Description: This study will include 180 participants. |
Treatment Experienced | Temporarily Closed |
